麗 珠 醫 藥 集 團 股 份 有 限 公 司 LIVZON PHARMACEUTICAL GROUP INC.* (a joint stock company incorporated in the People's Republic of China with limited liability) （ 於 中 公 司 ） 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 Livzon Pharmaceutical Group Inc. (the "Company") Notification of publication of (1) Annual Report 2024; (2) Circular dated 24 April 2025; (3) Notice and Proxy Form of the Annual General Meeting for the Year 2024; and (4) Notice and Proxy Form of the 2025 First Class Meeting of H Shareholders (the "Current Corporate C ...

麗 珠 醫 藥 集 團 股 份 有 限 公 司 LIVZON PHARMACEUTICAL GROUP INC.* (a joint stock company incorporated in the People's Republic of China with limited liability) （ 於 中 司 ） 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 (Stock code 股份代號: 1513) NOTIFICATION LETTER 通知信函 24 April 2025 Dear Non-Registered Holder(Note), Livzon Pharmaceutical Group Inc.(the "Company") Notification of publication of (1) Annual Report 2024; (2) Circular dated 24 April 2025; (3) Notice and Proxy Form of the Annual General Meeting for the Year 2024; and (4) N ...

Financial Performance - In 2024, Livzon Pharmaceutical Group achieved a revenue of RMB 11,812.34 million and a net profit attributable to shareholders of RMB 2,061.10 million[10]. - The company achieved a total revenue of RMB 12,430.04 million, with a year-on-year decrease of 4.97%[21]. - The net profit attributable to shareholders was RMB 1,953.65 million, reflecting a decline of 8.31% compared to the previous year[21]. - The company reported a net cash flow from operating activities of RMB 2,061.10 million, showing a significant increase of 51.80%[21]. - The company’s basic earnings per share for the year was RMB 2.10, with a diluted earnings per share of RMB 2.24[21]. - The company reported a total operating revenue for the year 2024 of RMB 11,812,338,854.68, representing a decrease of 4.97% compared to RMB 12,430,038,325.82 in 2023[106]. - The net profit attributable to shareholders increased by 5.50% to RMB 2,061,095.80 million in 2024[54]. - The company reported a gross margin of 45%, maintaining a stable margin compared to the previous year[37]. Research and Development - Research and development (R&D) investment accounted for 8.84% of total revenue, focusing on gastrointestinal, reproductive assistance, and mental health fields[14]. - The company has 45 products in the pipeline, including 23 innovative drugs and high-barrier complex formulations[14]. - Livzon has introduced six new projects through business development collaborations, enhancing its R&D pipeline[16]. - AI technology has been integrated into the entire R&D process, significantly improving efficiency[16]. - The company plans to increase investment in innovative drug research and development, focusing on core therapeutic areas such as digestive, mental health, and reproductive health[19]. - The company is focusing on self-research and business development (BD) to drive innovation, with a particular emphasis on gastrointestinal, reproductive, and neurological fields[73]. - The company has multiple products in various stages of clinical trials, including 3 in Phase III and 2 in Phase I[80]. - The company has established a modular and flat R&D management system to improve efficiency in project management and resource allocation[73]. Market Expansion - The company is expanding its market presence from emerging markets to Europe and the United States, optimizing its product offerings[17]. - Livzon is expanding its market presence in Southeast Asia, aiming to increase sales by 25% in that region[37]. - The company is actively pursuing international partnerships to introduce advanced technologies and expand its competitive products into global markets[93]. - The company has established branches in Malaysia and offices in Brazil, India, Spain, Vietnam, and Turkey to enhance its global commercialization strategy[101]. Product Development - Livzon plans to launch three new products in the next fiscal year, focusing on innovative drug development and biotechnology[37]. - The company has initiated Phase III clinical trials for a recombinant anti-IL-17A/F monoclonal antibody for psoriasis, aiming for market approval by 2025[76]. - The company has received approvals for three products during the reporting period, including potassium bismuth citrate granules and hydrochloride pramipexole tablets (8mg)[81]. - The company is focusing on high clinical value products, with a complete matrix of assisted reproductive products expected to enhance market presence[79]. - The company is advancing its research in traditional Chinese medicine, targeting mental health and chronic diseases, with two products expected to report this year[79]. Compliance and Sustainability - The company maintains a 100% compliance rate with GMP inspections for all production lines of listed products[18]. - The company has received MSCI ESG AAA rating for two consecutive years and was recognized as the "Best Progress Company" in the 2024 S&P Global Sustainability Yearbook[19]. - The company integrates sustainable development goals into management performance assessments, promoting green production and social responsibility[94]. - The company has established a standardized public welfare management system focusing on rural revitalization, education support, medical assistance, and disaster response, contributing to local farmers' income through the "Huangqi Industry Revitalization" project[95]. Financial Management - The company reported a total investment amount of RMB 1,711,305,473.04, representing a 134.54% increase compared to RMB 729,635,150.00 in the previous year[161]. - The company has established risk management measures for foreign exchange and commodity futures derivatives to mitigate market risks associated with currency and commodity price fluctuations[171]. - The company has not engaged in speculative derivative investments during the reporting period[172]. - The company has implemented strict internal controls to reduce operational risks related to derivative trading[171]. Customer and Supplier Relations - The average duration of the top five customers' relationship with the company is 16.60 years, indicating strong customer loyalty[114]. - The company’s total revenue from the top five customers was RMB 947,987,674.38, representing 8.10% of the total annual sales, slightly down from 8.19% in 2023[115]. - The total procurement amount from the top five suppliers was RMB 706,067,451.82, which accounted for 32.15% of the total procurement, an increase from 26.06% in 2023[119].

Stock Code 股份代號 : 1513 (A joint stock company incorporated in the People's Republic of China with limited liability) （在中華人民共和國註冊成立的股份有限公司） www.livzon.com.cn 2024 Environmental, Social and Governance Report 環境、社會及管治報告 * For identication purpose only 僅供識別 Evergreen Life, Bright Future & Wisdom 環境、社會及管治報告 Environmental, Social and Governance Report 2024 麗珠世界 生命常青 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc. | 1 ABOUT THIS REPORT | | 4 | | --- | --- | --- | | 2 CHAIRMAN'S MESSAGE | | 8 | | | 3 ABOUT THE COMPAN ...

Environmental, Social and Governance Report 環境、社會及管治報告 * For identication purpose only 僅供識別 Stock Code 股份代號 : 1513 (A joint stock company incorporated in the People's Republic of China with limited liability) （在中華人民共和國註冊成立的股份有限公司） www.livzon.com.cn 2024 Evergreen Life, Bright Future & Wisdom 麗珠世界 生命常青 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc. 環境、社會及管治報告 Environmental, Social and Governance Report 2024 | 1 關於本報告 | | 4 | | --- | --- | --- | | 2 董事長致辭 | | 8 | | 3 關於本公司 | | 12 | | 3.1 | 公司業務 | 13 | | 3.2 | ...

证券代码：000513、01513 证券简称：丽珠集团、丽珠医药 公告编号：2025-035 丽珠医药集团股份有限公司 关于召开 2024 年度股东大会、 2025 年第一次 A 股类别股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东大会届次：丽珠医药集团股份有限公司（以下简称"公司"）2024 年度股东大会、2025 年第一次 A 股类别股东会。 2、股东大会的召集人：公司董事会。公司已于 2025 年 4 月 23 日召开了第 十一届董事会第二十四次会议，审议通过了《关于召开公司 2024 年度股东大会、 2025 年第一次 A 股类别股东会及 2025 年第一次 H 股类别股东会的议案》。 3、会议召开的合法、合规性：本次股东大会会议的召开符合有关法律、行 政法规、部门规章、规范性文件、深交所业务规则和《公司章程》等规定。 4、会议召开的日期、时间： （1）现场会议召开日期、时间： ①2024 年度股东大会召开日期、时间：2025 年 5 月 29 日（星期四）下午 2:00； ②2025 年第一次 A 股类 ...

证券代码：000513、01513 证券简称：丽珠集团、丽珠医药 公告编号：2025-032 丽珠医药集团股份有限公司 第十一届监事会第十三次会议决议公告 本公司及监事会全体成员保证信息披露内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 丽珠医药集团股份有限公司（以下简称"公司"）第十一届监事会第十三次 会议于 2025 年 4 月 23 日以现场和通讯表决相结合的方式召开，会议通知已于 2025 年 4 月 9 日以电子邮件形式发送，现场会议地址为珠海市金湾区创业北路 38 号丽珠工业园总部大楼 9 楼会议室，本次会议应参会监事 3 人，实际参会监 事 3 人，本次会议的召开符合有关法律、行政法规、部门规章、规范性文件和公 司章程的规定，经与会监事认真审议，作出如下决议： 一、审议通过《丽珠医药集团股份有限公司 2025 年第一季度报告》 公司本次注销部分股票期权，符合《上市公司股权激励管理办法》和《2022 年股票期权激励计划（修订稿）》的相关规定，履行了必要的审议程序，同意公 司对 2022 年股票期权激励计划首次授予股票期权第一个行权期内尚未行权的 38.4045 万份股票期权，以及不符 ...

证券代码：000513、01513 证券简称：丽珠集团、丽珠医药 公告编号：2025-031 丽珠医药集团股份有限公司 第十一届董事会第二十四次会议决议公告 本公司及董事会全体成员保证信息披露内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、审议通过《丽珠医药集团股份有限公司 2024 年度环境、社会及管治报 告》 表决结果：同意 11 票，反对 0 票，弃权 0 票。 公司《2024 年度环境、社会及管治报告》已于本公告日披露于巨潮资讯网 （www.cninfo.com.cn）、香港交易及结算所有限公司网站（www.hkexnews.hk） 及本公司网站（www.livzon.com.cn）。 二、审议通过《丽珠医药集团股份有限公司 2025 年第一季度报告》 丽珠医药集团股份有限公司（以下简称"公司"）第十一届董事会第二十四 次会议于 2025 年 4 月 23 日以现场和通讯表决相结合的方式召开，会议通知已于 2025 年 4 月 9 日以电子邮件形式发送，现场会议地址为珠海市金湾区创业北路 38 号丽珠工业园总部大楼 9 楼会议室，本次会议应参会董事 11 人，实际参会董 事 11 人 ...

证券代码：000513、01513 证券简称：丽珠集团、丽珠医药 公告编号：2025-034 丽珠医药集团股份有限公司 关于注销2022年股票期权激励计划部分股票期权的公告 本公司及董事会全体成员保证信息披露内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 丽珠医药集团股份有限公司（以下简称"公司"或"丽珠集团"）于 2025 年 4 月 23 日召开了第十一届董事会第二十四次会议，审议通过了《关于注销 2022 年股票期权激励计划部分股票期权的议案》。现将相关事项说明如下： 一、公司 2022 年股票期权激励计划已履行的相关程序 1、2022 年 8 月 29 日，公司召开了第十届董事会第三十四次会议，审议通 过了《关于公司〈2022 年股票期权激励计划（草案）〉及其摘要的议案》《关于 公司〈2022 年股票期权激励计划实施考核管理办法〉的议案》《关于提请公司股 东大会授权董事会办理 2022 年股票期权激励计划相关事宜的议案》。独立董事就 《2022 年股票期权激励计划（草案）》发表了独立意见。 4、2022 年 10 月 11 日，公司披露了《监事会关于 2022 年股票期权激励计 划首次授 ...

Revenue and Profit - The company's revenue for Q1 2025 was CNY 3,180,547,599.31, a decrease of 1.92% compared to CNY 3,242,814,513.73 in the same period last year[7] - Net profit attributable to shareholders increased by 4.75% to CNY 636,707,931.59 from CNY 607,823,809.46 year-on-year[7] - Basic and diluted earnings per share rose by 9.23% to CNY 0.71 from CNY 0.65 in the same period last year[7] - The company's operating revenue for the current period is RMB 3,180,547,599.31, a decrease of 1.92% from RMB 3,242,814,513.73 in the previous period[27] - The net profit attributable to shareholders of the parent company is RMB 636,707,931.59, up 4.76% from RMB 607,823,809.46 in the previous period[27] Cash Flow - The net cash flow from operating activities decreased by 21.59% to CNY 724,730,912.38 compared to CNY 924,248,920.31 in the previous year[7] - Total cash inflow from operating activities was RMB 3,427,996,327.57, down from RMB 3,508,763,815.99, reflecting a decline of 2.3%[29] - Cash outflow from operating activities increased to RMB 2,703,265,415.19, compared to RMB 2,584,514,895.68, marking an increase of 4.6%[29] - The net cash flow from investing activities was -RMB 221,749,900.37, an improvement from -RMB 457,336,601.18 in the previous period[29] - Cash inflow from investing activities totaled RMB 32,290,697.41, significantly higher than RMB 6,035,760.64 previously[29] - Cash outflow from investing activities decreased to RMB 254,040,597.78 from RMB 463,372,361.82, a reduction of 45.2%[29] - The net cash flow from financing activities was -RMB 487,915,315.07, an improvement from -RMB 654,613,688.15 in the previous period[29] - Total cash inflow from financing activities was RMB 630,140,000.00, down from RMB 721,939,862.90, a decrease of 12.7%[29] - The cash and cash equivalents at the end of the period amounted to RMB 10,821,444,006.06, slightly up from RMB 10,787,974,836.57[29] Assets and Liabilities - Total assets at the end of the reporting period were CNY 24,485,271,838.40, a slight increase of 0.12% from CNY 24,455,825,697.18 at the end of the previous year[8] - The company's equity attributable to shareholders increased by 2.19% to CNY 14,165,648,873.87 from CNY 13,862,334,189.33 at the end of the previous year[8] - The total liabilities decreased to RMB 9,109,970,328.17 from RMB 9,550,079,103.14, reflecting a reduction of approximately 4.62%[25] - Current assets totaled RMB 16,465,641,594.27, compared to RMB 16,419,980,644.30 at the beginning of the year[23] - Cash and cash equivalents stood at RMB 10,830,774,329.69, slightly up from RMB 10,827,146,984.92 at the start of the year[23] - The company's inventory decreased to RMB 1,900,256,033.70 from RMB 1,997,642,296.29 at the beginning of the year[23] - Long-term equity investments increased to RMB 1,061,082,396.62 from RMB 1,056,220,316.06[23] - The company has a total of 8,019,630,244.13 in non-current assets, slightly down from 8,035,845,052.88 at the beginning of the year[23] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 52,367, with 52,348 being A-share shareholders[16] - The company reported a total of 306,769,189 shares held by Hong Kong Central Clearing (Agent) Limited, representing 33.66% of the total shares[17] - Health元药业集团股份有限公司 holds 221,376,789 shares, accounting for 24.29% of the total shares[17] - The total number of shares repurchased by the company reached 9,425,955 A-shares, accounting for 1.03% of the total share capital, with a total expenditure of RMB 341,957,191.15[18] - The company also repurchased 7,245,300 H-shares, representing 0.80% of the total share capital, with a total expenditure of HKD 190,692,395.00[19] Expenses and Future Plans - Research and development expenses for the current period are RMB 216,076,782.61, down 9.25% from RMB 238,173,559.46 in the previous period[27] - The company reported a decrease in sales expenses to RMB 800,020,635.30 from RMB 876,113,247.33, a reduction of about 8.66%[27] - The company's financial expenses showed a slight improvement, with net financial income of RMB -56,040,353.34 compared to RMB -54,508,308.03 in the previous period[27] - The company plans to continue focusing on market expansion and new product development to drive future growth[27] Audit Information - The company did not undergo an audit for the first quarter report[30]